SHINPOONG PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14,100 KRW | -2.02% |
|
-0.91% | +4.29% |
| Apr. 24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| 2023 | South Korean Shares Continue Losing Streak Amid High Interest Rate Woes | MT |
ETFs positioned on Shinpoong Pharmaceutical Co.,Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 0 M€ | +3.22% | - | |
| 0.00% | 0 M€ | +4.12% | - | |
| 0.00% | 0 M€ | +7.77% | - | |
| 0.00% | 0 M€ | +5.23% | - | |
| 0.00% | 0 M€ | +5.36% | - | |
| 0.00% | 0 M€ | +3.45% | - |
Shin Pooong Pharm., Co. Ltd is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. The Company's product portfolio consists of antibiotics, cardiovascular drugs, anti-cancer drugs, psychoneurotic drugs, antirheumatic drugs, antidiabetics, antifungal agents, antihistamines, antiviral agents, benign prostatic hyperplasia (BPH) drugs and trichogens. The Company also provides active pharmaceutical ingredients (APIs) synthesized by the Company, including non-steroidal anti-inflammatory drugs (NSAIDs), cardiovascular drugs, anti-ulcer drugs, respiratory drugs, antispasmodics drugs and others. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +4.29% | 561M | |
| +20.83% | 43.57B | |
| +22.27% | 22.7B | |
| +16.41% | 14.32B | |
| +11.11% | 13.42B | |
| +45.91% | 11.83B | |
| -6.86% | 6.98B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.41% | 5.51B |
- Stock Market
- Equities
- A019170 Stock
- Funds and ETFs Shinpoong Pharmaceutical Co.,Ltd